Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11313523 | 0.83 | CYP1A2 (0.57) | CYP1A2CYP2A6ALDH1A1NPC1POLB | |
| SCHEMBL16523084 | 0.80 | CYP1A2 (0.44) | CYP1A2CYP2A6ALDH1A1NPC1POLB | |
| SCHEMBL13305087 | 0.80 | ALDH1A1 (0.53) | CYP1A2CYP2A6ALDH1A1NPC1POLB | |
| SCHEMBL17532771 | 0.76 | MAPT (0.55) | CYP1A2CYP2A6ALDH1A1NPC1POLB | |
| SCHEMBL23976318 | 0.75 | NR4A2 (0.52) | CYP1A2ALDH1A1NPC1POLBRAB9A | |
| SCHEMBL30225346 | 0.75 | NR4A2 (0.52) | CYP1A2ALDH1A1NPC1POLBRAB9A | |
| SCHEMBL276949 | 0.75 | ALDH1A1 (0.52) | CYP1A2ALDH1A1NPC1POLBRAB9A | |
| SCHEMBL276948 | 0.75 | NPC1 (0.50) | CYP1A2ALDH1A1NPC1POLBRAB9A | |
| SCHEMBL1097563 | 0.75 | PDPK1 (0.57) | CYP1A2ALDH1A1NPC1POLBRAB9A | |
| SCHEMBL18459133 | 0.75 | NPC1 (0.50) | CYP1A2ALDH1A1NPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123968-A1 | RNA TARGETING COMPOUNDS AND USES THEREOF | RANAR THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20240018175-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS AND ELECTRONIC EQUIPMENT INCLUDING THE LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-11825740-B2 | Amine compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-21 | — | — | US | disclosed |
| US-11825740-B2 | Amine compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-21 | — | — | US | disclosed |
| US-20230354694-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, ELECTONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE INCLUDING THE LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744146-B2 | Amine-based compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-08-29 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11690289-B2 | Organic compound containing heterocyclic ring and having low lumo properties, and organic electroluminescent device using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-27 | — | — | US | disclosed |
| WO-2023110138-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| WO-2013007663-A1 | 2-BENZYLSULFANYL[1,3,4]-OXADIAZOLE DERIVATIVES, AND MEDICAL USE THEREOF | Technische Universität Darmstadt (DE) | 2013-01-17 | — | — | WO | disclosed |
| EP-2310389-B1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| WO-2010140802-A1 | NOVEL ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | DOW ADVANCED DISPLAY MATERIALS, LTD. (KR) | 2010-12-09 | — | — | WO | disclosed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009143477-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| EP-1337251-B1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007022501-A2 | USEFUL INDOLE COMPOUNDS | MICROBIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | CYP1A2 1279/4885CYP2A6 1471/4885ALDH1A1 918/4885 |
| US-20240018175-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS AND ELECTRONIC EQUIPMENT INCLUDING THE LIGHT-EMITTING DEVICE | GPX1, LAGE3, NFE2L2 | CYP1A2 268/4885CYP2A6 814/4885ALDH1A1 17/4885 |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | CYP1A2 1830/4885CYP2A6 1911/4885ALDH1A1 1674/4885 |
| US-11690289-B2 | Organic compound containing heterocyclic ring and having low lumo properties, and organic electroluminescent device using the same | LEF1, PPOX, LIMK1 | CYP1A2 77/4885CYP2A6 1011/4885ALDH1A1 111/4885 |
| US-11744146-B2 | Amine-based compound and organic light-emitting device including the same | AOC2, AOC1, EML4 | CYP1A2 456/4885CYP2A6 2759/4885ALDH1A1 76/4885 |
| US-20070203209-A1 | Useful indole compounds | TPH2, HRH2, HRH1 | CYP1A2 672/4885CYP2A6 1511/4885ALDH1A1 1494/4885 |
| US-11825740-B2 | Amine compound and organic light-emitting device including the same | AOC2, AOC1, AOC3 | CYP1A2 126/4885CYP2A6 2184/4885ALDH1A1 19/4885 |
| US-20230354694-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, ELECTONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE INCLUDING THE LIGHT-EMITTING DEVICE | LAGE3, ELP1, EML4 | CYP1A2 1405/4885CYP2A6 1245/4885ALDH1A1 98/4885 |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, PIK3R1, PIK3R5 | CYP1A2 3274/4885CYP2A6 3568/4885ALDH1A1 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.